Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Foghorn Therapeutics stock | $20.61

Own Foghorn Therapeutics stock in just a few minutes.

Updated . What changed?

Fact checked

Foghorn Therapeutics Inc is a biotechnology business based in the US. Foghorn Therapeutics shares (FHTX) are listed on the NASDAQ and all prices are listed in US Dollars. Foghorn Therapeutics employs 85 staff and has a market cap (total outstanding shares value) of USD$629.1 million.

How to buy shares in Foghorn Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Foghorn Therapeutics. Find the stock by name or ticker symbol: FHTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Foghorn Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$20.61, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Foghorn Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Foghorn Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Foghorn Therapeutics share price

Use our graph to track the performance of FHTX stocks over time.

Foghorn Therapeutics shares at a glance

Information last updated 2020-12-02.
Latest market closeUSD$20.61
52-week rangeUSD$14.03 - USD$21.04
50-day moving average USD$16.8926
200-day moving average USD$16.8926
Wall St. target priceUSD$25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Foghorn Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Foghorn Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Foghorn Therapeutics price performance over time

Historical closes compared with the close of $20.61 from 2020-12-09

1 week (2021-01-12) 8.13%
1 month (2020-12-18) -20.36%
3 months (2020-10-16) N/A
6 months (2020-07-16) N/A
1 year (2020-01-16) N/A
2 years (2019-01-16) N/A
3 years (2018-01-16) N/A
5 years (2016-01-16) N/A

Foghorn Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$629.1 million

TTM: trailing 12 months

Shorting Foghorn Therapeutics shares

There are currently 19,697 Foghorn Therapeutics shares held short by investors – that's known as Foghorn Therapeutics's "short interest". This figure is 7.1% up from 18,396 last month.

There are a few different ways that this level of interest in shorting Foghorn Therapeutics shares can be evaluated.

Foghorn Therapeutics's "short interest ratio" (SIR)

Foghorn Therapeutics's "short interest ratio" (SIR) is the quantity of Foghorn Therapeutics shares currently shorted divided by the average quantity of Foghorn Therapeutics shares traded daily (recently around 393940). Foghorn Therapeutics's SIR currently stands at 0.05. In other words for every 100,000 Foghorn Therapeutics shares traded daily on the market, roughly 50 shares are currently held short.

To gain some more context, you can compare Foghorn Therapeutics's short interest ratio against those of similar companies.

However Foghorn Therapeutics's short interest can also be evaluated against the total number of Foghorn Therapeutics shares, or, against the total number of tradable Foghorn Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Foghorn Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Foghorn Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0011% of the tradable shares (for every 100,000 tradable Foghorn Therapeutics shares, roughly 1 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Foghorn Therapeutics.

Find out more about how you can short Foghorn Therapeutics stock.

Foghorn Therapeutics share dividends

We're not expecting Foghorn Therapeutics to pay a dividend over the next 12 months.

Foghorn Therapeutics overview

Foghorn Therapeutics Inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small-molecule enzymatic inhibitor of BRG1 and BRM for the treatment of acute myeloid leukemia and uveal melanoma; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing preclinical and discovery programs, including selective BRM targeting non-small-cell lung cancer; and selective ARID1B modulators for bladder, ovarian, and endometrial cancer. It has a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site